Amarin Corp Plc (AMRN)

[ziploc_1]

Regulatory approval is expected in China by mid year according to AB...This can change the whole picture for Amarin...It can mean...
-High volumes of sales of Vascepa in China
-Lower prices for Vascepa in China...
-leading to lower prices for Vaskepa in Europe and Vascepa in the U.S.
-leading to an AG in the U.S.
-leading to more profits from the increased volumes, which can fund Amarin to advance new products such as a FDC and MND-2119(which are not presently consistent with Amarin"s recent policy to conserve cash)

This is reminiscent of John Thero's old prediction that Vascepa's destiny is not to be a price play...but a volume play!